Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways

Parkin, 2005, Global cancer statistics, 2002, CA Cancer J Clin, 55, 74, 10.3322/canjclin.55.2.74 Llovet, 2008, Molecular targeted therapies in hepatocellular carcinoma, Hepatology, 48, 1312, 10.1002/hep.22506 Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857 Villanueva, 2011, Targeted therapies for hepatocellular carcinoma, Gastroenterology, 140, 1410, 10.1053/j.gastro.2011.03.006 Whittaker, 2011, The role of signaling pathways in the development and treatment of hepatocellular carcinoma, Oncogene, 29, 4989, 10.1038/onc.2010.236 Manning, 2007, AKT/PKB signaling: navigating downstream, Cell, 129, 1261, 10.1016/j.cell.2007.06.009 Zoncu, 2011, MTOR: from growth signal integration to cancer, diabetes and ageing, Nat Rev Mol Cell Biol, 12, 21, 10.1038/nrm3025 Villanueva, 2008, Pivotal role of mTOR signaling in hepatocellular carcinoma, Gastroenterology, 135, 1972, 10.1053/j.gastro.2008.08.008 Ruggero, 2005, The Akt of translational control, Oncogene, 24, 7426, 10.1038/sj.onc.1209098 Calvisi, 2010, Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma, Gastroenterology, 140, 1071, 10.1053/j.gastro.2010.12.006 Galicia, 2010, Expansion of hepatic tumor progenitor cells in Pten-null mice requires liver injury and is reversed by loss of AKT2, Gastroenterology, 139, 2170, 10.1053/j.gastro.2010.09.002 Calvisi, 2006, Ubiquitous activation of Ras and Jak/Stat pathways in human HCC, Gastroenterology, 130, 1117, 10.1053/j.gastro.2006.01.006 Tsuda, 1989, Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma, Jpn J Cancer Res, 80, 196, 10.1111/j.1349-7006.1989.tb02290.x Challen, 1992, Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas, J Hepatol, 14, 342, 10.1016/0168-8278(92)90181-N Edwin, 2009, Intermolecular interactions of Sprouty proteins and their implications in development and disease, Mol Pharmacol, 76, 679, 10.1124/mol.109.055848 Lo, 2006, Sprouty and cancer: the first terms report, Cancer Lett, 242, 141, 10.1016/j.canlet.2005.12.032 Fong, 2006, Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma, Cancer Res, 66, 2048, 10.1158/0008-5472.CAN-05-1072 Lee, 2008, Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer, Hepatology, 47, 1200, 10.1002/hep.22169 Lee, 2010, Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis, Hepatology, 52, 506, 10.1002/hep.23681 Ho, 2012, AKT and N-Ras coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR, FOXM1/SKP2, and c-Myc pathways, Hepatology, 55, 833, 10.1002/hep.24736 Carlson, 2005, Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse, Proc Natl Acad Sci USA, 102, 17059, 10.1073/pnas.0502974102 Frith, 1994, Tumours of the liver, IARC Sci Publ, 223 Xia, 2008, Emperipolesis, entosis and beyond: dance with fate, Cell Res, 18, 705, 10.1038/cr.2008.64 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Levine, 2010, The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes, Science, 330, 1340, 10.1126/science.1193494 David, 2010, HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer, Nature, 463, 364, 10.1038/nature08697 Mazurek, 2011, Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells, Int J Biochem Cell Biol, 43, 969, 10.1016/j.biocel.2010.02.005 Christofk, 2008, The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth, Nature, 452, 230, 10.1038/nature06734 Yang, 2011, Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation, Nature, 480, 118, 10.1038/nature10598 Luo, 2011, Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1, Cell, 145, 732, 10.1016/j.cell.2011.03.054